Remdesivir News and Research

RSS

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

9 May 2022

Study investigates the cause of lymphopenia as seen in COVID-19 patients

Researchers explored the underlying mechanism resulting in thymic atrophy and subsequent lymphopenia in COVID-19 patients.

9 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

SARS-CoV-2 develops partial resistance to the antiviral drug remdesivir in cell culture

The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.

5 May 2022

Fourth dose of COVID-19 vaccine reduced death among hospitalized patients during Omicron wave in Israel

Researchers investigated the effect of a fourth dose of the coronavirus disease 2019 (COVID-19) vaccine in patients with severe disease symptoms.

2 May 2022

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

A new study describes the development of new molecules with inhibitory activity against the SARS-CoV-2 viral main protease (Mpro) enzyme, based on rattlesnake venom.

29 Apr 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with COVID-19.

27 Apr 2022

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

A recent review paper, published in the MDPI’s specialized journal COVID, highlights key features of the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – and examines the potential and roadblocks in using renewable marine resources in the fight against the coronavirus disease 2019 (COVID-19).

24 Apr 2022

Interleukin-6 levels predict early withdrawal of COVID-19 patients from mechanical ventilation

Researchers reported that plasma IL-6 levels in patients with ARDS due to COVID-19 could predict early withdrawal from mechanical ventilation.

22 Apr 2022

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.

21 Apr 2022

Why cheap, older drugs that might treat covid never get out of the lab

In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.

19 Apr 2022

New, longest documented case of persistent acute SARS-CoV-2 infection

Researchers describe a 16-month-old case of SARS-CoV-2 infection in an immunocompromised individual.

18 Apr 2022

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Researchers demonstrate that avasimibe-mediated inhibition of ACAT blocks the entry and fusion of SARS-CoV-2 in different cell types.

18 Apr 2022

Study finds dexamethasone and remdesivir treatment in hospitalized COVID-19 patients is associated with reduced neurological complications

Researchers investigated the potential of therapeutic drugs, remdesivir and dexamethasone, when used alone or in combination on neurological complications that arise in COVID-19 affected individuals.

14 Apr 2022

COVID-19 may affect a group of biochemical reactions called one-carbon metabolism

A new study addresses the relationship between SARS-CoV-2 to the metabolism of one-carbon molecules in the host, suggesting new therapeutic pathways.

13 Apr 2022

Scientific statement from the American Heart Association on COVID-19 and cardiovascular complications in children and adolescents

A recent scientific statement published in Circulation reviewed the current knowledge on COVID-19.

13 Apr 2022

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Heart complications are uncommon, yet treatable for children and young adults after COVID-19 disease or SARS-CoV-2 infection, according to a new scientific statement from the American Heart Association that details what has been learned about how to treat, manage and even prevent cardiovascular complications from the SARS-CoV-2 virus in youth.

12 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022